Harvard Bioscience (NASDAQ:HBIO – Get Free Report) had its target price lowered by Benchmark from $5.50 to $4.50 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a ...

It's a multi-tasking skincare device with six different functions: Electroporation to increase product efficacy and ...

When it comes to achieving glass skin, Hailey Bieber has it down pat. After all, she is the founder of Rhode, the skincare ...

MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAb in their systems.

MaxCyte (NASDAQ:MXCT – Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on ...

To permanently access these supporting documents, fill out the short form below. At MaxCyte, we share your passion for the discovery, development, and manufacturing of next generation therapies, ...

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Now in its third year, the trial is led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the University of Pennsylvania. It is funded by the Coronavirus ...

CRISPR libraries enable scientists to systematically investigate gene functions, identify novel drug targets, and develop personalized therapies.